NASDAQ:PCRXPacira Biosciences Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Pacira Biosciences Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $35.69 +2.30 (+6.89 %) (As of 04/10/2020 08:57 AM ET) Add Compare Share Today's Range$33.61Now: $35.69▼$35.7650-Day Range$28.40MA: $37.40▼$50.7052-Week Range$27.46Now: $35.69▼$51.35Volume608,450 shsAverage Volume922,281 shsMarket Capitalization$1.50 billionP/E RatioN/ADividend YieldN/ABeta1.2 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure. It offers EXPAREL, a non-opioid medication administered at the time of surgery to control pain while reducing opioid requirements; and iovera system, a handheld cryoanalgesia device used to deliver controlled doses of cold temperature only to targeted nerves. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was founded in 2006 and is based in Parsippany, New Jersey.Read More Beat the Market (BTM) Rank™ 4.4 Analyst's Opinion Consensus RatingPacira Biosciences has received a consensus rating of Buy. The company's average rating score is 2.73, and is based on 11 buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $53.67, Pacira Biosciences has a potential upside of 50.4% from its current price of $35.69.Amount of Analyst CoveragePacira Biosciences has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.8 Community Rank Outperform VotesPacira Biosciences has received 726 “outperform” votes. (Add your “outperform” vote.)Underperform VotesPacira Biosciences has received 548 “underperform” votes. (Add your “underperform” vote.)Community SentimentPacira Biosciences has received 56.99% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Pacira Biosciences and other stocks. Vote “Outperform” if you believe PCRX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PCRX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldPacira Biosciences does not currently pay a dividend.Dividend GrowthPacira Biosciences does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Pacira Biosciences insiders have sold 1,078.04% more of their company's stock than they have bought. Specifically, they have bought $91,250.00 in company stock and sold $1,074,958.00 in company stock.Percentage Held by InsidersOnly 5.80% of the stock of Pacira Biosciences is held by insiders. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Pacira Biosciences are expected to grow by 139.73% in the coming year, from $0.73 to $1.75 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pacira Biosciences is -127.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pacira Biosciences is -127.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioPacira Biosciences has a PEG Ratio of 1.39. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioPacira Biosciences has a P/B Ratio of 4.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 4.4Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.81 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:PCRX Previous Symbol CUSIP69512710 CIK1396814 Webhttp://www.pacira.com/ Phone973-254-3560Debt Debt-to-Equity Ratio0.98 Current Ratio3.79 Quick Ratio3.25Price-To-Earnings Trailing P/E RatioN/A Forward P/E Ratio48.89 P/E Growth1.39 Sales & Book Value Annual Sales$421.03 million Price / Sales3.56 Cash Flow$1.85 per share Price / Cash Flow19.33 Book Value$8.51 per share Price / Book4.19Profitability EPS (Most Recent Fiscal Year)$0.86 Net Income$-11,020,000.00 Net Margins-2.62% Return on Equity10.81% Return on Assets4.71%Miscellaneous Employees518 Outstanding Shares42,030,000Market Cap$1.50 billion Next Earnings Date5/7/2020 (Estimated) OptionableOptionable Receive PCRX News and Ratings via Email Sign-up to receive the latest news and ratings for PCRX and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:PCRX Rates by TradingView Pacira Biosciences (NASDAQ:PCRX) Frequently Asked Questions How has Pacira Biosciences' stock been impacted by COVID-19 (Coronavirus)? Pacira Biosciences' stock was trading at $35.19 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, PCRX shares have increased by 1.4% and is now trading at $35.69. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Pacira Biosciences? 15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pacira Biosciences in the last year. There are currently 4 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Pacira Biosciences. When is Pacira Biosciences' next earnings date? Pacira Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, May 7th 2020. View our earnings forecast for Pacira Biosciences. How were Pacira Biosciences' earnings last quarter? Pacira Biosciences Inc (NASDAQ:PCRX) announced its quarterly earnings results on Thursday, February, 20th. The company reported $0.56 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.21 by $0.35. The business had revenue of $122.42 million for the quarter, compared to analysts' expectations of $122.04 million. Pacira Biosciences had a positive return on equity of 10.81% and a negative net margin of 2.62%. The company's quarterly revenue was up 28.7% on a year-over-year basis. During the same period in the prior year, the firm earned $0.47 EPS. View Pacira Biosciences' earnings history. What guidance has Pacira Biosciences issued on next quarter's earnings? Pacira Biosciences updated its FY 2020 Pre-Market earnings guidance on Thursday, February, 20th. The company provided EPS guidance of for the period. The company issued revenue guidance of $485-500 million, compared to the consensus revenue estimate of $495.91 million. What price target have analysts set for PCRX? 15 analysts have issued 1 year price objectives for Pacira Biosciences' stock. Their forecasts range from $38.00 to $85.00. On average, they anticipate Pacira Biosciences' stock price to reach $53.67 in the next twelve months. This suggests a possible upside of 50.4% from the stock's current price. View analysts' price targets for Pacira Biosciences. What are Wall Street analysts saying about Pacira Biosciences stock? Here are some recent quotes from research analysts about Pacira Biosciences stock: 1. According to Zacks Investment Research, "Pacira changed its name to Pacira BioSciences after acquiring MyoScience in April 2019 following which, it added the latter’s iovera system to its portfolio.. Pacira's top line mainly comprises contribution from its marketed drug Exparel, which continues to maintain momentum. The drug’s label expansion to include administration via nerve block for prolonged regional analgesia is expected to further boost sales in the days ahead. Pacira’s agreement with Nuance for the development and commercialization of Exparel in China is a tailwind. The company's shares have outperformed the industry in the past year. However, Pacira remains heavily dependent on Exparel for growth. Therefore, any regulatory setback for the drug will severely hurt the stock." (3/27/2020) 2. Stifel Nicolaus analysts commented, "We are upgrading shares of PCRX to Hold as we believe the near-term competitive threat from HRTX’s HTX-011 will be less of a factor over the next 12 months and the recent strength in the stock indicates to us that the stock is fairly valued at these levels. While PCRX’s Exparel revenues came in a little shy of 1Q19 consensus, we believe the recent price increase on Exparel, the lack of a competitive entry from HRTX and the favorable reimbursement scheme in the ASC setting should allow PCRX to achieve its 2019 Exparel guidance, in our view. Our revised 2019 Exparel estimates are now at the midpoint of management’s guidance of ~$400-$410 million (vs. consensus of ~$403 million). Additionally, we incorporate PCRX’s recent acquisition, Iovera, into our model and raise our target price to $45 a share." (5/2/2019) Has Pacira Biosciences been receiving favorable news coverage? News articles about PCRX stock have been trending very negative on Friday, according to InfoTrie. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Pacira Biosciences earned a news sentiment score of -3.3 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutPacira Biosciences. Who are some of Pacira Biosciences' key competitors? Some companies that are related to Pacira Biosciences include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), AbbVie (ABBV), Zoetis (ZTS), Allergan (AGN), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Horizon Therapeutics (HZNP), Nektar Therapeutics (NKTR), Corcept Therapeutics (CORT) and Zogenix (ZGNX). What other stocks do shareholders of Pacira Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Pacira Biosciences investors own include Gilead Sciences (GILD), ACADIA Pharmaceuticals (ACAD), Celgene (CELG), Clovis Oncology (CLVS), NVIDIA (NVDA), Micron Technology (MU), Netflix (NFLX), Alibaba Group (BABA), Bausch Health Companies (BHC) and Exelixis (EXEL). Who are Pacira Biosciences' key executives? Pacira Biosciences' management team includes the following people: Mr. David M. Stack, Chairman & CEO (Age 69)Mr. Charles A. Reinhart III, CPA, M.B.A., Chief Financial Officer (Age 58)Ms. Kristen Williams, Chief Admin. Officer & Sec. (Age 45)Dr. Richard Scranton M.D., MPH, Chief Medical Officer (Age 52)Mr. Dennis McLoughlin, Chief Commercial Officer (Age 53) What is Pacira Biosciences' stock symbol? Pacira Biosciences trades on the NASDAQ under the ticker symbol "PCRX." Who are Pacira Biosciences' major shareholders? Pacira Biosciences' stock is owned by many different retail and institutional investors. Top institutional investors include State of Alaska Department of Revenue (0.09%). Company insiders that own Pacira Biosciences stock include Andreas Wicki, Charles A Reinhart III, Charles Anthony Laranjeira, David M Stack, Dennis Mcloughlin, Gary W Pace, John P Phd Longenecker, Kristen Marie Williams, Lauren Bullaro Riker, Mark A Kronenfeld, Paul J Hastings, Richard Scranton and Roy Winston. View institutional ownership trends for Pacira Biosciences. Which institutional investors are buying Pacira Biosciences stock? PCRX stock was bought by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue. Company insiders that have bought Pacira Biosciences stock in the last two years include Gary W Pace, Mark A Kronenfeld, and Roy Winston. View insider buying and selling activity for Pacira Biosciences. How do I buy shares of Pacira Biosciences? Shares of PCRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Pacira Biosciences' stock price today? One share of PCRX stock can currently be purchased for approximately $35.69. How big of a company is Pacira Biosciences? Pacira Biosciences has a market capitalization of $1.50 billion and generates $421.03 million in revenue each year. The company earns $-11,020,000.00 in net income (profit) each year or $0.86 on an earnings per share basis. Pacira Biosciences employs 518 workers across the globe. View additional information about Pacira Biosciences. What is Pacira Biosciences' official website? The official website for Pacira Biosciences is http://www.pacira.com/. How can I contact Pacira Biosciences? Pacira Biosciences' mailing address is 5 SYLVAN WAY SUITE 300, PARSIPPANY NJ, 07054. The company can be reached via phone at 973-254-3560 or via email at [email protected] This page was last updated on 4/10/2020 by MarketBeat.com StaffFeatured Article: What are retained earnings?
